RTI for COVID-19 Response Data: Vaccine Contracts, Oxygen Procurement, and Excess Deaths

The COVID-19 pandemic was, among other things, one of the largest public procurement events in independent India's history. Vaccines were purchased at prices negotiated between the government and private manufacturers. Oxygen concentrators and medical-grade oxygen were allocated among states during the devastating second wave. Ventilators, PPE kits, N95 masks, and testing kits were procured and distributed at scale. Every rupee spent on these items came from public funds — budgetary allocations, emergency funds, PM CARES disbursements routed through government ministries, and NDRF/SDRF releases to state governments.

Public money, spent by public authorities, for a public purpose. That is precisely the domain the Right to Information Act, 2005 was designed to cover.

And yet a great deal of this data — vaccine prices, oxygen allocation decisions, PPE contract terms, and the full extent of COVID-19 mortality — has remained either partially disclosed or actively contested. RTI is the statutory instrument that gives every citizen the legal right to demand more. This guide explains what you can ask, which public authorities hold the information, and how to handle the exemptions these authorities are likely to invoke when they would rather not answer.

Why COVID-19 Is an RTI Topic

The instinct to treat the pandemic response as a medical or humanitarian event — something outside the ordinary accountability architecture — is understandable but incorrect from a legal standpoint. The RTI Act, 2005 applies to all public authorities as defined in Section 2(h), regardless of whether they are operating during a declared pandemic, a national emergency, or ordinary times. There is no pandemic exception to the RTI Act.

The procurement decisions made during COVID-19 were consequential in ways that extend well beyond health policy. Vaccine prices were negotiated through contracts whose terms the government initially declined to disclose. The prices paid by the Indian government were publicly compared with prices paid by other countries, generating legitimate public concern about value for public money. The oxygen allocation process during April and May 2021 — when the second wave overwhelmed hospitals and thousands of patients died — was characterised by government officials as orderly even as videos of people dying outside hospitals without oxygen circulated nationwide. Excess mortality estimates from independent researchers suggested the official COVID-19 death count was a fraction of the true toll; the methodology used to generate the official count has not been fully explained.

These are not peripheral matters. They go to how decisions were made, whether public money was spent appropriately, and whether the government's public communications accurately reflected reality. RTI is the mechanism by which citizens can put these questions to the authorities that hold the answers.

Vaccine Procurement: What to Ask and Who Holds the Information

Ministry of Health and Family Welfare (MoHFW)

The Ministry of Health and Family Welfare is the central government authority that managed the National COVID-19 Vaccination Programme. It is unambiguously a public authority under Section 2(h)(a) — established by the Constitution and government notifications — and therefore fully subject to the RTI Act. Second appeals go to the Central Information Commission (CIC).

The most important RTI questions to direct to MoHFW are:

• Per-dose procurement cost for each COVID-19 vaccine procured by the Central Government: Covaxin (manufactured by Bharat Biotech International Limited), Covishield (manufactured by Serum Institute of India), and Sputnik V (manufactured by Dr. Reddy's Laboratories under licence). Specifically ask for the price per dose stated in each procurement agreement between the Government of India and the vaccine manufacturer, for each batch or tranche of procurement.
• Total doses procured by the Central Government under each vaccine, including the timeline of procurement orders.
• State-wise vaccine allocation — how many doses of each vaccine type were allocated to each state and Union Territory during the first and second phases of the vaccination programme, and what allocation methodology was used.
• Vaccine wastage data: The percentage of doses wasted at state level — doses drawn from vials but not administered, or vials damaged before use — disaggregated by state and time period.
• Procurement agreements and contract terms with vaccine manufacturers, to the extent not protected by applicable exemptions (discussed below).

What MoHFW may say: The ministry has previously cited Section 8(1)(d) — commercial confidence — when asked about vaccine procurement prices. That response is contestable, and the argument for contesting it is set out in the exemptions section below.

CDSCO: The Regulatory File for Emergency Use Authorisation

The Central Drugs Standard Control Organisation (CDSCO) functions under MoHFW as India's national drug regulatory authority. It granted Emergency Use Authorisation (EUA) to COVID-19 vaccines — including Covaxin and Covishield — during late 2020 and early 2021. CDSCO is a public authority. Second appeal goes to the CIC.

What to ask:

• The complete regulatory file — meaning all documents submitted by the vaccine manufacturer to CDSCO as part of the EUA application, including clinical trial phase data, safety and efficacy summaries, and risk management plans. Note that manufacturers may claim Section 8(1)(d) commercial confidence over portions of this data, but CDSCO's own regulatory assessment file — the agency's internal analysis, committee deliberations, and decision record — should be accessible independently of the manufacturer's proprietary data.
• Whether a Subject Expert Committee (SEC) reviewed the vaccine applications, the composition of the SEC, the minutes of SEC meetings, and the basis on which the SEC recommended EUA.
• Any post-marketing surveillance data or adverse event reports filed with CDSCO after vaccines were rolled out.
• The scientific basis for CDSCO's determination that EUA criteria were met — specifically, what evidence base was considered sufficient for emergency authorisation, and how it compared to the standard approval criteria.

CDSCO's regulatory decision-making file is not the manufacturer's proprietary data. The agency's own work product — its analysis, its committee minutes, its approval rationale — was created by a public authority in the exercise of a statutory function and cannot be withheld as commercial confidence.

National Health Authority and CoWIN Data

The National Health Authority (NHA), which administered the CoWIN vaccination management platform, is a public authority under MoHFW. Second appeal goes to the CIC.

What to ask:

• State-wise and district-wise vaccination coverage data, disaggregated by dose number (first dose, second dose, precaution dose), vaccine type, and age group.
• Demographic breakdowns of vaccination — what proportion of vaccinated individuals were from rural versus urban areas, from BPL categories, from scheduled caste or scheduled tribe populations — at the aggregate level.
• CoWIN system design documents: The technical specifications, data architecture, and privacy impact assessments prepared before CoWIN's rollout.
• Data breach assessments: Whether CoWIN experienced any data security incidents and what action was taken.

Oxygen Allocation During the Second Wave: What to Ask and Who Holds It

The April-May 2021 second wave produced one of the most visible failures of the COVID-19 response: a shortage of medical-grade oxygen that left hospitals scrambling and patients dying. The government established Empowered Group 2 (EG-2) specifically to manage oxygen allocation. The Supreme Court of India constituted a 12-member National Task Force on oxygen allocation. Understanding what decisions were made, by whom, and on what basis requires targeting multiple public authorities.

Ministry of Steel and Ministry of Health: The EG-2 Allocation Orders

Empowered Group 2 was chaired by the Ministry of Steel (because most oxygen in India was produced by steel plants) and coordinated with MoHFW. Both ministries are public authorities. Second appeals go to the CIC.

What to ask:

• State-wise oxygen allocation orders issued by EG-2 during April and May 2021 — the specific quantities allocated to each state, in metric tonnes per day, and the dates on which these orders were issued.
• The methodology used to determine allocations: What data inputs — hospitalisation rates, ICU occupancy, oxygen consumption figures — were used to calculate each state's allocation? Was a formula applied consistently, or were allocations determined by other means?
• Whether any state received less than it requested, and if so, why.
• Correspondence between EG-2 and state governments during the peak oxygen shortage period, including any communications about allocation shortfalls.
• Minutes of EG-2 meetings during April and May 2021.

These questions go to the heart of whether oxygen was allocated equitably and whether the allocation process was responsive to documented need on the ground.

State Health Departments: Intra-State Oxygen Distribution

The state government's health department is the relevant public authority for understanding how centrally allocated oxygen was distributed within the state — which districts received how much, which hospitals were prioritised, and whether any hospital's reported oxygen shortage was reflected in the allocation records.

File this RTI with the CPIO at the state health department of the relevant state. Second appeal goes to the State Information Commission (SIC) of that state.

Ask for: district-wise and hospital-wise oxygen allocation data during the shortage period; whether any hospital sent an SOS communication to the state government about oxygen, and what response was given; and the state government's own records of COVID-19 patient deaths attributed to oxygen shortage, if any such record was maintained.

The Supreme Court National Task Force

The Supreme Court of India constituted a National Task Force on oxygen allocation by order dated 8 May 2021. The Task Force's reports and correspondence are part of the Supreme Court's record in the proceedings (WP (Civil) No. 3 of 2021). These are court documents — they can be accessed through the Supreme Court Registry's copy processes and not via RTI — but any reports submitted by Task Force members who are public authority officials may also be accessible via RTI to the relevant ministry.

PPE and Medical Equipment Procurement

Ministry of Health and Department of Pharmaceuticals

The central government made large-scale procurements of N95 masks, PPE kits, and ventilators during the pandemic. The Ministry of Health and Family Welfare and the Department of Pharmaceuticals (under the Ministry of Chemicals and Fertilizers) are both public authorities. Second appeals go to the CIC.

What to ask:

• Procurement contracts for PPE: The names of suppliers, quantities contracted, and per-unit prices paid for N95 masks, PPE kits, and personal protective equipment procured by the Central Government.
• Ventilator procurement: How many ventilators were procured under central government schemes, from which manufacturers, at what price per unit, and how were they distributed among states and health facilities?
• HLL Lifecare procurements: HLL Lifecare Limited is a Central Government PSU under the Ministry of Health that was involved in manufacturing and procuring PPE during the pandemic. As a government-owned company substantially controlled by the Central Government, it is a public authority. RTI to HLL Lifecare can seek procurement and production data for centrally manufactured PPE.

For PPE procured using PM CARES disbursements and then distributed through government ministries: even if PM CARES itself has resisted RTI (as discussed in a separate blog on the PM CARES Fund), the ministries that received PM CARES-funded equipment and distributed it to states and hospitals are public authorities. Their records of what they received, how much it cost (at the ministry level), and how it was distributed are accessible through RTI.

COVID-19 Death Data and Excess Mortality

This may be the most consequential area of COVID-19 RTI — and the one where the gap between official figures and independently estimated reality is largest. Multiple peer-reviewed studies, including analyses published in international medical journals, estimated that the true number of COVID-related deaths in India was dramatically higher than the official count. The methodology used to generate official COVID-19 death figures has not been fully explained in the public domain.

Registrar General of India: Civil Registration Data

The Registrar General of India (RGI), which operates under the Ministry of Home Affairs, manages the Civil Registration System — the legal framework under which births and deaths are registered across India. It publishes the Sample Registration System (SRS) and annual vital statistics reports. The RGI is a public authority. Second appeal goes to the CIC.

What to ask:

• District-wise registered death counts for 2020 and 2021, compared against district-wise registered death counts for 2018 and 2019 as a baseline. This is the data from which excess mortality calculations are made. Ask specifically for the number of deaths registered in each district for each calendar year from 2018 through 2021 — four years of data that allows the calculation of baseline mortality and excess mortality.
• Whether the RGI has prepared any internal analysis of excess mortality during the COVID-19 pandemic period, and if so, provide a copy.
• The degree of completeness of death registration data for 2020 and 2021 — what proportion of deaths are estimated to go unregistered, by state.
• The civil registration data for cause of death coding: For the years 2020 and 2021, what proportion of registered deaths were attributed to COVID-19, and what methodology was used for cause of death attribution?

Some of this aggregate data has been released proactively by the government. RTI can push for more granular data — district-level rather than state-level, monthly rather than annual — that paints a more precise picture of excess mortality.

State Civil Registration Authorities

Each state maintains its own civil registration authority (typically under the state's Home Department or Health Department), which collects death registration data before aggregating it to the RGI. Several states have been the subject of RTI applications and media reports on this topic.

File with the CPIO at the state's Directorate of Economics and Statistics or the State Civil Registration Authority. Second appeal goes to the SIC of that state.

Ask for: monthly death registration data by district for 2019, 2020, and 2021; any analysis prepared by the state on COVID-19 mortality that was not published; and records of deaths attributed to oxygen shortage at government hospitals during April-May 2021.

ICMR: Seroprevalence and Mortality Research

The Indian Council of Medical Research (ICMR) is an autonomous body under MoHFW that conducted the national seroprevalence surveys — large-scale studies that estimated what proportion of India's population had been exposed to SARS-CoV-2. ICMR is a public authority (as a body substantially financed by the Central Government). Second appeal goes to the CIC.

What to ask:

• Full data from all four national seroprevalence rounds — disaggregated results by state, district, age group, and rural-urban split, to the extent not already publicly available.
• Any ICMR mortality research on COVID-19 excess deaths — internal studies, commissioned reports, or research funded by ICMR on the gap between official COVID-19 mortality figures and estimated true mortality.
• ICMR's internal documentation on the clinical management protocols issued for COVID-19 treatment and the evidence basis for each protocol revision.

Section 8 Exemptions That Will Be Invoked — and How to Counter Them

Public authorities holding COVID-19 procurement data have an obvious interest in invoking exemptions to avoid disclosure. There are three exemptions that will come up most frequently, and in each case there is a clear counter-argument.

Section 8(1)(d): Commercial Confidence

The government — and vaccine and equipment manufacturers who have been consulted as third parties under Section 11 — are likely to invoke Section 8(1)(d), which exempts from disclosure "information including commercial confidence, trade secrets or intellectual property, the disclosure of which would harm the competitive position of a third party, unless the competent authority is satisfied that larger public interest warrants the disclosure of such information."

How to counter this: The test under Section 8(1)(d) is not whether a private party provided the information, but whether disclosure would harm that party's competitive position. The per-dose price the government paid for a vaccine that has already been administered to hundreds of millions of people does not, in any meaningful sense, harm the manufacturer's competitive position going forward — the contract is complete, the doses have been delivered, and the price is historical public expenditure data. There is no ongoing commercial negotiation that price disclosure would undermine.

More importantly, the very text of Section 8(1)(d) contains an internal override: "unless the competent authority is satisfied that larger public interest warrants the disclosure of such information." And crucially, Section 8(2) of the RTI Act provides a blanket public interest override that applies across all Section 8(1) exemptions: where the public interest in disclosure outweighs the harm to the protected interest, disclosure is required. The price of vaccines purchased with public money under a national vaccination programme — involving the health of every Indian citizen — is a paradigm case for the public interest override. The CIC has applied Section 8(2) in analogous procurement contexts. Your First Appeal and Second Appeal should explicitly invoke this override.

Section 8(1)(e): Fiduciary Capacity

Some public authorities may claim that vaccine price negotiations were conducted in a fiduciary capacity — that the government holds this information in trust for the manufacturer and cannot disclose it. This argument is difficult to sustain once a contract has been executed. The fiduciary or negotiation-phase protection that prevents disclosure of bargaining positions during active negotiations does not extend indefinitely to completed contracts. Once the procurement is done, the government holds a completed contract, not an ongoing negotiating position.

How to counter this: In your First Appeal, note that the contract has been executed and the procurement is complete. There is no ongoing fiduciary relationship that would be damaged by disclosure of a historical price. The information the government holds is a record of expenditure of public funds — not a continuing negotiating position — and the fiduciary exception does not apply to historical procurement data.

"Information Not Held" and the Transfer Mechanism

A common tactic is for the CPIO at one ministry to respond that the information is "not held" by that department. In procurement involving multiple agencies, this may actually be true for any individual department — but the remedy is not to abandon the RTI. Under Section 6(3) of the RTI Act, where a CPIO cannot supply information because it relates to another public authority, the CPIO is required to transfer the application to the correct public authority within five days.

How to counter this: If you receive a "not held" response, ask the CPIO: which public authority, in your opinion, holds this information? Under Section 6(3), the CPIO is obligated to transfer, not merely to decline. If the CPIO does not transfer and gives no useful guidance, file RTI directly with the most likely custodian — for vaccine procurement prices, that is typically the MoHFW's procurement cell or the Department of Pharmaceuticals.

Practical Tips for COVID-19 RTI Applications

Getting results from COVID-19 RTI applications requires the same discipline as any complex RTI — precision in what you ask and strategic choice of which authority to approach first.

Be specific about the commodity, the time period, and the quantity. An RTI asking for "all COVID-19 procurement data" will be returned as overly broad and unwieldy. An RTI asking for "the per-dose price paid under each procurement agreement for Covishield doses procured by the Central Government between January 2021 and December 2021, the total number of doses covered by each agreement, and the name of the supplier" is specific, answerable, and much harder to legitimately refuse.

Ask for records, not opinions. RTI is a right to access information in the form of records, documents, and data held by the public authority — not a right to compel the government to create new analyses or answer general questions. Ask for "the state-wise oxygen allocation orders issued by EG-2 during April 2021" — not "why was my state allocated insufficient oxygen." The former asks for an existing record; the latter asks for a policy justification.

File with the right authority first. Before spending thirty days waiting for a transfer, think through who actually holds the data. Vaccine procurement contracts are held by MoHFW (and potentially the Department of Pharmaceuticals). Oxygen allocation orders are held by the Ministry of Steel and MoHFW. Excess mortality civil registration data is held by the RGI and state civil registration authorities. CDSCO holds the EUA regulatory file. Filing with the correct CPIO from the start is more efficient than relying on transfers.

Expect delays — and use the appeal mechanism. COVID-19 procurement data is politically sensitive. CPIOs will miss deadlines; some will treat non-response as a way to avoid disclosure. Under Section 7(1) of the RTI Act, a CPIO who fails to respond within 30 days is deemed to have refused — and that deemed refusal triggers your right to file a First Appeal under Section 19(1) within 30 days of the expiry of the response period. A First Appeal costs nothing and creates a formal record. Second Appeal to the CIC is the escalation route that has teeth — Information Commissioners can impose penalties on CPIOs for unjustified delays and refusals under Section 20 of the Act.

Use Section 8(2) proactively. When you file the original RTI application — not just in the appeal — it can be useful to include a brief note invoking Section 8(2) in anticipation of a commercial confidence or fiduciary refusal. Stating in the application itself that you consider any Section 8(1)(d) objection to be outweighed by the public interest in disclosure of vaccine procurement data serves notice on the CPIO that you are aware of the override provision and intend to pursue it.

The Broader Accountability Picture

RTI is not the only mechanism available — and for some COVID-19 data, it may not be the fastest. The Comptroller and Auditor General of India (CAG) has the constitutional mandate to audit government expenditure and has audited COVID-19 response spending. CAG audit reports, once tabled in Parliament, are public documents available on the CAG website. Parliamentary questions on the floor of both Houses have produced on-record government answers about vaccine procurement, oxygen allocation, and PPE distribution. The Supreme Court proceedings on oxygen allocation generated detailed affidavits from the Central Government that are on the public record.

But RTI is distinct from all of these in one fundamental respect: it is a right that every individual citizen can exercise, without needing to be a Member of Parliament, without needing access to a parliamentary researcher's resources, and without needing to file a PIL in the Supreme Court. The CAG audits what the CAG decides to audit. Parliamentary questions depend on elected representatives choosing to ask them. RTI puts the demand-side power in the hands of the citizen — any citizen, filing from any part of India, asking for any specific record held by any public authority.

For COVID-19 accountability, that matters. The pandemic touched every Indian. The money spent on the pandemic response belonged to every Indian. The RTI Act gives every Indian the legal right to know how that money was spent, on whose authority, at what prices, and with what results.

If you want help drafting RTI applications for vaccine procurement data, oxygen allocation records, or COVID-19 mortality data from MoHFW, CDSCO, the National Health Authority, the RGI, or ICMR — RTISathi.com provides guides on how to frame precise RTI questions for each public authority, sample application language for handling commercial confidence refusals under Section 8(2), and step-by-step guidance on filing First and Second Appeals when the initial response is inadequate or absent.